<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00247611</url>
  </required_header>
  <id_info>
    <org_study_id>R01MH066684</org_study_id>
    <secondary_id>R01MH066684</secondary_id>
    <secondary_id>DAHBR 9A-ASPG</secondary_id>
    <nct_id>NCT00247611</nct_id>
  </id_info>
  <brief_title>Improving Treatment Adherence in HIV-Infected Individuals</brief_title>
  <official_title>Changing ART Adherence Behavior: The Lifewindows Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Connecticut</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Connecticut</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will develop and evaluate the efficacy of an individualized, interactive, computer
      software program delivered in conjunction with clinical care in increasing and supporting
      antiretroviral therapy adherence in HIV-infected individuals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      When antiretroviral therapy (ART) is taken correctly, it can dramatically improve the health
      and well-being of HIV-infected individuals. However, when the treatment regimen is not
      followed carefully, the therapy can be ineffective in managing one's HIV, and also can allow
      for the development of strains of HIV that may be resistant to treatment. Effective ART
      adherence interventions can help patients to avoid potentially serious individual and public
      health consequences of suboptimal adherence, but such interventions are often expensive and
      too intensive for clinics to support offering over time to their patients. This study will
      develop and evaluate the effectiveness of an individualized, interactive, computer-software
      intervention program delivered in clinical care in increasing ART adherence in HIV-infected
      individuals. Because the intervention is a software program, clinic resources required for
      implementation and sustaining availability over time are minimized.

      Participants in this ~18-month study were recruited from one of 5 participating clinics that
      provide HIV care and randomly assigned to control (an assessment only version of the
      software) or intervention (assessment and tailored intervention software) arm. Participants
      completed their assigned task in concert with their regularly scheduled HIV medical care
      visits (but no more frequently than once a month). Primary outcomes were measured at each
      medical visit. The effect of the adherence intervention was evaluated through comparison of
      treatment and control arm adherence reports over time and VL.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AIDS Clinical Trials Group (ACTG) 3-day Recall Measure of Doses Taken</measure>
    <time_frame>Measured at each clinical care visit over 18 months of participation</time_frame>
    <description>This measure asks participants to report the number of doses taken on each of the past 3-days, relative to number he or she was prescribed to take, and produces a % adherence score. For this study, adherence over the past 3-days was established for each medication separately then averaged over the full regimen. For main outcomes, perfect vs imperfect adherence was evaluated. Significant findings on perfect/imperfect adherence were followed with sensitivity tests to determine if lowest threshold (eg., 90%, 80%, 70% adherence) effect was maintained.
See: Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient care committee &amp; adherence working group of the outcomes committee of the adult AIDS clinical trials group (AACTG). AIDS Care. 2000;12(3):255-266.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Scale Measure of Adherence to ART</measure>
    <time_frame>Measured at each clinical visit over 18 months of participation</time_frame>
    <description>This measure asks participants to rate their adherence over the past 3 to 4 weeks using a line that marks from 0 to 100% of doses taken. For this study, this item was asked for each antiretroviral in one's regimen and a total score was produced by averaging all reports. For main outcomes, perfect vs imperfect adherence was evaluated.
See: Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS.2002;16:269-77</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viral Load Count</measure>
    <time_frame>Measured over 18 months</time_frame>
    <description>Viral load data extracted from medical records beginning 30 days prior to baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">594</enrollment>
  <condition>HIV Antiretroviral Therapy (ART) Adherence</condition>
  <condition>Health Behavior</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will receive the control condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the LifeWindows Intervention sessions</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>LifeWindows Intervention Sessions</intervention_name>
    <description>At each clinical care visit, intervention arm participants use the full LifeWindows program, which includes welcome and assessment surveys and also includes the active intervention modules. ART adherence promotion intervention activities are tailored to the participant's assessment responses. Participants select which activities he or she wishes to use which culminates in an adherence specific goal.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>At each clinical care visit, control arm participants use the portion of the LifeWindows software program that provides a welcome from the avatar and collection of assessment items/surveys.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-infected

          -  English-speaking

          -  Currently receiving treatment at one of the participating sites

          -  Currently receiving antiretroviral therapy

        Exclusion Criteria:

          -  Marked cognitive impairment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey D. Fisher, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Connecticut</affiliation>
  </overall_official>
  <overall_official>
    <last_name>K. Rivet Amico*, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Connecticut (*co-PI)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Deborah H. Cornman*, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Connecticut (*co-PI)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William A. Fisher*, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Western Ontario (*co-PI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Connecticut Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030-3212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale-New Haven Hospital Nathan Smith Clinic</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Saint Raphael</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waterbury Hospital</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/21452051</url>
    <description>PubMed record of results article</description>
  </link>
  <results_reference>
    <citation>Fisher JD, Amico KR, Fisher WA, Cornman DH, Shuper PA, Trayling C, Redding C, Barta W, Lemieux AF, Altice FL, Dieckhaus K, Friedland G; LifeWindows Team. Computer-based intervention in HIV clinical care setting improves antiretroviral adherence: the LifeWindows Project. AIDS Behav. 2011 Nov;15(8):1635-46. doi: 10.1007/s10461-011-9926-x.</citation>
    <PMID>21452051</PMID>
  </results_reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2005</study_first_submitted>
  <study_first_submitted_qc>October 31, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2005</study_first_posted>
  <results_first_submitted>August 1, 2013</results_first_submitted>
  <results_first_submitted_qc>November 26, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 20, 2013</results_first_posted>
  <last_update_submitted>November 26, 2013</last_update_submitted>
  <last_update_submitted_qc>November 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Connecticut</investigator_affiliation>
    <investigator_full_name>Jeffrey Fisher</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>AIDS</keyword>
  <keyword>Antiretroviral Medication Adherence</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>HIV + patients were recruited via provider referral and notices about the study posted in five large HIV care clinics in Connecticut, USA.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>Participants will receive the control condition</description>
        </group>
        <group group_id="P2">
          <title>Intervention</title>
          <description>Participants will receive the LifeWindows Intervention sessions</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Baselined</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="304">Participants randomized</participants>
                <participants group_id="P2" count="290">Participants randomized</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="287">Randomized participants who completed at least 2 adherence assessments/sessions</participants>
                <participants group_id="P2" count="277">Randomized participants who completed at least 2 adherence assessments/sessions</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Completed baseline, never placed on ARVs</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Completed baseline only</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Intention to Treat Sample</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="304">Participants randomized</participants>
                <participants group_id="P2" count="290">Participants randomized</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="287">Randomized participants who completed at least 2 adherence assessments/sessions</participants>
                <participants group_id="P2" count="277">Randomized participants who completed at least 2 adherence assessments/sessions</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>On Protocol Sample</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="287">ITT sample participants</participants>
                <participants group_id="P2" count="277">ITT sample participants</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="176">Participants with no interruptions in ART receipt and completing 6 or more LifeWindows assessments</participants>
                <participants group_id="P2" count="152">Participants with no interruptions in ART receipt and completing 6 or more LifeWindows assessments</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="125"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline characteristics provided for randomized sample. Analyses were conducted on those with &gt;=2 adherence assessments for ITT.</population>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>Participants will receive the control condition</description>
        </group>
        <group group_id="B2">
          <title>Intervention</title>
          <description>Participants will receive the LifeWindows Intervention sessions</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="304"/>
            <count group_id="B2" value="290"/>
            <count group_id="B3" value="594"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Intent to Treat (ITT) Sample</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="301"/>
                    <measurement group_id="B2" value="284"/>
                    <measurement group_id="B3" value="585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>On Protocol (OP) The On-Protocol sample was derived from the ITT sample who also had completed &gt;=6 assessments and had no ART receipt interruptions.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="174"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Intent to Treat (ITT) Sample</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.28" spread="8.01"/>
                    <measurement group_id="B2" value="46.76" spread="8.00"/>
                    <measurement group_id="B3" value="47" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Intent to Treat (ITT) Sample</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="185"/>
                    <measurement group_id="B2" value="180"/>
                    <measurement group_id="B3" value="365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>On Protocol (OP)</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Intent to Treat (ITT) Sample</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="304"/>
                    <measurement group_id="B2" value="290"/>
                    <measurement group_id="B3" value="594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AIDS Clinical Trials Group (ACTG) 3-day Recall Measure of Doses Taken</title>
        <description>This measure asks participants to report the number of doses taken on each of the past 3-days, relative to number he or she was prescribed to take, and produces a % adherence score. For this study, adherence over the past 3-days was established for each medication separately then averaged over the full regimen. For main outcomes, perfect vs imperfect adherence was evaluated. Significant findings on perfect/imperfect adherence were followed with sensitivity tests to determine if lowest threshold (eg., 90%, 80%, 70% adherence) effect was maintained.
See: Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient care committee &amp; adherence working group of the outcomes committee of the adult AIDS clinical trials group (AACTG). AIDS Care. 2000;12(3):255-266.</description>
        <time_frame>Measured at each clinical care visit over 18 months of participation</time_frame>
        <population>Intent to treat included all participants with &gt;=2 adherence assessments; OP sample further restricted this sample to those with &gt;=6 assessments and no treatment interruptions over 18-months of participation. Multiple pairwise comparison replaced missing values. HLM was used for over-time analyses on proportion reporting perfect adherence.</population>
        <group_list>
          <group group_id="O1">
            <title>Control (ITT Sample %)</title>
            <description>287 (94%) of the 304 randomized to control</description>
          </group>
          <group group_id="O2">
            <title>Intervention (ITT Sample)</title>
            <description>277 (96%) of the 290 randomized to Intervention condition</description>
          </group>
          <group group_id="O3">
            <title>Control (On Protocol Sample)</title>
            <description>176 (61%) of the ITT included control arm participants</description>
          </group>
          <group group_id="O4">
            <title>Intervention (On Protocol)</title>
            <description>152 (55%) of the ITT included intervention arm participants</description>
          </group>
        </group_list>
        <measure>
          <title>AIDS Clinical Trials Group (ACTG) 3-day Recall Measure of Doses Taken</title>
          <description>This measure asks participants to report the number of doses taken on each of the past 3-days, relative to number he or she was prescribed to take, and produces a % adherence score. For this study, adherence over the past 3-days was established for each medication separately then averaged over the full regimen. For main outcomes, perfect vs imperfect adherence was evaluated. Significant findings on perfect/imperfect adherence were followed with sensitivity tests to determine if lowest threshold (eg., 90%, 80%, 70% adherence) effect was maintained.
See: Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient care committee &amp; adherence working group of the outcomes committee of the adult AIDS clinical trials group (AACTG). AIDS Care. 2000;12(3):255-266.</description>
          <population>Intent to treat included all participants with &gt;=2 adherence assessments; OP sample further restricted this sample to those with &gt;=6 assessments and no treatment interruptions over 18-months of participation. Multiple pairwise comparison replaced missing values. HLM was used for over-time analyses on proportion reporting perfect adherence.</population>
          <units>percent with 100% adherence</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="277"/>
                <count group_id="O3" value="176"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 LifeWindows Visit (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.89"/>
                    <measurement group_id="O2" value="75.46"/>
                    <measurement group_id="O3" value="74.86"/>
                    <measurement group_id="O4" value="77.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 LifeWindows Visits (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.36"/>
                    <measurement group_id="O2" value="82.48"/>
                    <measurement group_id="O3" value="81.50"/>
                    <measurement group_id="O4" value="85.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 LifeWindows Visits (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.15"/>
                    <measurement group_id="O2" value="80.16"/>
                    <measurement group_id="O3" value="84.09"/>
                    <measurement group_id="O4" value="84.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 LifeWindows Visits (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.92"/>
                    <measurement group_id="O2" value="81.78"/>
                    <measurement group_id="O3" value="80.11"/>
                    <measurement group_id="O4" value="81.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 LifeWindows Visits (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.41"/>
                    <measurement group_id="O2" value="87.13"/>
                    <measurement group_id="O3" value="82.86"/>
                    <measurement group_id="O4" value="88.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 LifeWindows Visits (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.25"/>
                    <measurement group_id="O2" value="82.46"/>
                    <measurement group_id="O3" value="81.61"/>
                    <measurement group_id="O4" value="83.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 LifeWindows Visits (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.73"/>
                    <measurement group_id="O2" value="85.61"/>
                    <measurement group_id="O3" value="79.70"/>
                    <measurement group_id="O4" value="87.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 LifeWindows Visits (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.82"/>
                    <measurement group_id="O2" value="88.54"/>
                    <measurement group_id="O3" value="79.00"/>
                    <measurement group_id="O4" value="91.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 LifeWindows Visits (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.02"/>
                    <measurement group_id="O2" value="87.14"/>
                    <measurement group_id="O3" value="81.58"/>
                    <measurement group_id="O4" value="89.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 LifeWindows Visits (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.12"/>
                    <measurement group_id="O2" value="80.70"/>
                    <measurement group_id="O3" value="71.93"/>
                    <measurement group_id="O4" value="84.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 LifeWindows Visits (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.21"/>
                    <measurement group_id="O2" value="78.57"/>
                    <measurement group_id="O3" value="68.42"/>
                    <measurement group_id="O4" value="83.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 LifeWindows Visits (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.13"/>
                    <measurement group_id="O2" value="90.63"/>
                    <measurement group_id="O3" value="73.08"/>
                    <measurement group_id="O4" value="88.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>13 LifeWindows Visits (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.00"/>
                    <measurement group_id="O2" value="87.50"/>
                    <measurement group_id="O3" value="65.00"/>
                    <measurement group_id="O4" value="85.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14 LifeWindows Visits (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.23"/>
                    <measurement group_id="O2" value="85.71"/>
                    <measurement group_id="O3" value="70.00"/>
                    <measurement group_id="O4" value="81.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For the ITT sample, the observed pattern of an increasing proportion of participants in the intervention arm reporting perfect adherence as time progressed from was associated with a p-value of 0.12, two-tailed alpha 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.12</p_value>
            <p_value_desc>The p-value was not adjusted for multiple comparisons, and thresholds for significance were 0.05 alpha two tailed.</p_value_desc>
            <method>HLM</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For the on protocol sample, study arm was associated with perfect ACTG-assessed 3-day ARV adherence at p = 0.024, alpha two-tailed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.024</p_value>
            <p_value_desc>The p-value was not adjusted for multiple comparisons, and thresholds for significance was 0.05 alpha, two tailed.</p_value_desc>
            <method>HLM</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Viral Load Count</title>
        <description>Viral load data extracted from medical records beginning 30 days prior to baseline.</description>
        <time_frame>Measured over 18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control (ITT Sample)</title>
            <description>287 (94%) of the 304 randomized to control</description>
          </group>
          <group group_id="O2">
            <title>Intervention (ITT Sample)</title>
            <description>277 (96%) of the 290 randomized to Intervention condition</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Load Count</title>
          <description>Viral load data extracted from medical records beginning 30 days prior to baseline.</description>
          <units>percentage with undetectable viral load</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 3 months (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.9"/>
                    <measurement group_id="O2" value="70.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-6 months (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.3"/>
                    <measurement group_id="O2" value="77.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-9 months (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.4"/>
                    <measurement group_id="O2" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9-12 months (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.1"/>
                    <measurement group_id="O2" value="76.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-15 months (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.2"/>
                    <measurement group_id="O2" value="76.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15-18 months (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.5"/>
                    <measurement group_id="O2" value="79.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For the ITT or OP samples, the significance threshold between groups over time for differential increases in proportion with suppressed (undetectable) viral load was p &gt; 0.50. The study was underpowered to detect differences in Viral load.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.50</p_value>
            <p_value_desc>No adjustments were made.</p_value_desc>
            <method>Generalized Linear Model (GLM)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Visual Analog Scale Measure of Adherence to ART</title>
        <description>This measure asks participants to rate their adherence over the past 3 to 4 weeks using a line that marks from 0 to 100% of doses taken. For this study, this item was asked for each antiretroviral in one’s regimen and a total score was produced by averaging all reports. For main outcomes, perfect vs imperfect adherence was evaluated.
See: Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS.2002;16:269-77</description>
        <time_frame>Measured at each clinical visit over 18 months of participation</time_frame>
        <population>Intent to treat included all participants with &gt;=2 adherence assessments; OP sample further restricted this sample to those with &gt;=6 assessments and no treatment interruptions over 18-months of participation. Multiple pairwise comparisons replaced missing values. HLM was used for over-time analyses on proportion reporting perfect adherence.</population>
        <group_list>
          <group group_id="O1">
            <title>Control (ITT Sample)</title>
            <description>287 (94%) of the 304 randomized to control</description>
          </group>
          <group group_id="O2">
            <title>Intervention (ITT Sample)</title>
            <description>277 (96%) of the 290 randomized to Intervention condition</description>
          </group>
          <group group_id="O3">
            <title>Control (On Protocol Sample)</title>
            <description>176 (61%) of the ITT included control arm participants</description>
          </group>
          <group group_id="O4">
            <title>Intervention (On Protocol Sample)</title>
            <description>152 (55%) of the ITT included intervention arm participants</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale Measure of Adherence to ART</title>
          <description>This measure asks participants to rate their adherence over the past 3 to 4 weeks using a line that marks from 0 to 100% of doses taken. For this study, this item was asked for each antiretroviral in one’s regimen and a total score was produced by averaging all reports. For main outcomes, perfect vs imperfect adherence was evaluated.
See: Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS.2002;16:269-77</description>
          <population>Intent to treat included all participants with &gt;=2 adherence assessments; OP sample further restricted this sample to those with &gt;=6 assessments and no treatment interruptions over 18-months of participation. Multiple pairwise comparisons replaced missing values. HLM was used for over-time analyses on proportion reporting perfect adherence.</population>
          <units>percent with 100% adherence</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="277"/>
                <count group_id="O3" value="176"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 LifeWindows Visit (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.61"/>
                    <measurement group_id="O2" value="46.15"/>
                    <measurement group_id="O3" value="45.71"/>
                    <measurement group_id="O4" value="45.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 LifeWindows Visits (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.27"/>
                    <measurement group_id="O2" value="47.81"/>
                    <measurement group_id="O3" value="43.35"/>
                    <measurement group_id="O4" value="47.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 LifeWindows Visits (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.69"/>
                    <measurement group_id="O2" value="47.77"/>
                    <measurement group_id="O3" value="42.05"/>
                    <measurement group_id="O4" value="49.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 LifeWindows Visits (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.21"/>
                    <measurement group_id="O2" value="48.44"/>
                    <measurement group_id="O3" value="40.34"/>
                    <measurement group_id="O4" value="44.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 LifeWindows Visits (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.79"/>
                    <measurement group_id="O2" value="50.99"/>
                    <measurement group_id="O3" value="41.14"/>
                    <measurement group_id="O4" value="50.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 LifeWindows Visits (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.83"/>
                    <measurement group_id="O2" value="49.12"/>
                    <measurement group_id="O3" value="45.98"/>
                    <measurement group_id="O4" value="51.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 LifeWindows Visits (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.89"/>
                    <measurement group_id="O2" value="41.67"/>
                    <measurement group_id="O3" value="40.60"/>
                    <measurement group_id="O4" value="46.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 LifeWindows Visits (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.09"/>
                    <measurement group_id="O2" value="40.63"/>
                    <measurement group_id="O3" value="34.00"/>
                    <measurement group_id="O4" value="42.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 LifeWindows Visits (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.46"/>
                    <measurement group_id="O2" value="38.57"/>
                    <measurement group_id="O3" value="30.26"/>
                    <measurement group_id="O4" value="39.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 LifeWindows Visits (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.41"/>
                    <measurement group_id="O2" value="36.84"/>
                    <measurement group_id="O3" value="28.07"/>
                    <measurement group_id="O4" value="36.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 LifeWindows Visits (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.66"/>
                    <measurement group_id="O2" value="30.95"/>
                    <measurement group_id="O3" value="23.68"/>
                    <measurement group_id="O4" value="29.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 LifeWindows Visits (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.13"/>
                    <measurement group_id="O2" value="31.25"/>
                    <measurement group_id="O3" value="23.08"/>
                    <measurement group_id="O4" value="23.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>13 LifeWindows Visits (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.00"/>
                    <measurement group_id="O2" value="41.67"/>
                    <measurement group_id="O3" value="25.00"/>
                    <measurement group_id="O4" value="33.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14 LifeWindows Visits (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.08"/>
                    <measurement group_id="O2" value="42.86"/>
                    <measurement group_id="O3" value="10.00"/>
                    <measurement group_id="O4" value="27.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For the ITT sample (t=586) the observed pattern of an increasing proportion of participants in the intervention arm reporting perfect adherence as time progressed from baseline was associated with a p-value of 0.12, alpha 0.05 two-tailed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.12</p_value>
            <p_value_desc>The p-value was not adjusted for multiple comparisons and is reported as 0.12 at alpha 0.05 two tailed</p_value_desc>
            <method>HLM</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For the on protocol sample the pattern of increased proportion of participants in the intervention arm reporting perfect adherence as time progressed from baseline was associated with a p-value of 0.12, alpha 0.05 two-tailed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.12</p_value>
            <p_value_desc>The p-value was not adjusted for multiple comparisons, and is reported as 0.12 at alpha 0.05 two tailed.</p_value_desc>
            <method>HLM</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Percentage of Participants Unemployed and on Disability</title>
        <time_frame>Data collected at Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>On Protocol (OP) Sample</title>
            <description>Post-hoc analysis of the participants provided &gt;=6 assessments with no ART receipt interruptions</description>
          </group>
          <group group_id="O2">
            <title>Total Excluded From OP Sample</title>
            <description>ITT sample excluded from the post-hoc analysis of the participants provided &gt;=6 assessments with no ART receipt interruptions (ITT - OP sample)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Unemployed and on Disability</title>
          <units>percentage of participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="328"/>
                <count group_id="O2" value="266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% of participants Unemployed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% of participants on Disability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value for difference in unemployment rate between On Protocol (OP) sample, and participants excluded from on protocol analysis.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value for difference of participants on disability between On Protocol (OP) sample, and participants excluded from on protocol analysis.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Patient enrollment to end of IRB annual renewals</time_frame>
      <desc>No adverse events occurred during the study</desc>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>Participants will receive the control condition</description>
        </group>
        <group group_id="E2">
          <title>Intervention</title>
          <description>Participants will receive the LifeWindows Intervention sessions</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="290"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The only empirical demonstration of LifeWindows outcomes to date
OP sample was defined a posteriori
Under-powered to detect changes in Viral Load</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Jeffrey Fisher, Principal Investigator</name_or_title>
      <organization>Center for Health, Intervention &amp; Prevention</organization>
      <phone>(860) 486-4940</phone>
      <email>jeffrey.fisher@uconn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

